Key points are not available for this paper at this time.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained use primarily due to their weight-reduction effects, although a regulatory review was undertaken for potential suicidality concern.
Schoretsanitis et al. (Tue,) studied this question.